| Venetoclax | Abbvie | ||
| 10,50,100 mg; Tablet, Oral |
More Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
| None | None | ||
| VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate | |||
|
Yes
| |||
| Venclexta | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ** *****'* | ********* | ********* | ********* | *** ********* | ********* | **** ** *** **, **** | ******* ***** ********* ************ | ******* ***** ********* ************ | ********* | *** ********* | **** ** *** **, **** |
| ******* | *** ********* | ********* | *** ********* | *** ********* | ********* | ******* ***** ********* ************ | ******* ***** ********* ************ | ******* ***** ********* ************ | ********* | *** ********* | ******* ***** ********* ************ |
| ***** *** *********** ***** ** ** *********-******** ***** | *********** ******* ** * **** ** ****-**** ******** **** * ********* ***-* ********* | *********** ******* ** * **** ** ****-**** ******** **** * ********* ***-* ********* | ****-******** ***** *********** ********** ** *********-******** ***** | *********** ******* ** * **** ** ****-**** ******** **** * ********* ***-* ********* | *********** ******* ** * **** ** ****-**** ******** **** * ********* ***-* ********* | ********* ******** ****** *** *** ********* ** ****** *** ****** *** ********** ******** | ***** *** *********** ***** ** ** *********-******** ***** | *********-******** ****** *** *** ********* ** ****** *** ****** *** ********** ******** | ***** *** *********** ***** ** *-(*-{[*-(*-************)-*,*-****************-*-**-*-**]****** *********-*-**)-*-({*-*****-*-[(**********-**-*****-*-********)*****]******}********)-*-(**-*******[*,*-*]*******-*-*****)********* | *********** ******* ** * **** ** ****-**** ******** **** * ********* ***-* ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ** *****'* | *** \ ********* | *** **, **** | ******* / ********* ******* | ********* ******** | ******* *** **** *** **** **** |
| ******* | *** \ ********* | *** **, **** | ******* ***** ********* ************ | **** | ******* *** **** *** **** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|